Apricot Capital

Etern is developing small molecule innovative drugs for oncology therapies.

GRIT Biotechnology is engaged in research and development of tumor infiltration lymphocytes immunotherapy for curing solid tumors. The company is based in Shanghai, China.

Forerunner Medical (Shanghai) Co., Ltd. develops and manufactures medical devices for minimally invasive treatment. It primarily develops and produces low-temperature plasma radiofrequency generators and electrodes for sport medicine, disk demo-pression, and ENT treatment applications. Its products include plasma radiofrequency systems; and electrodes for joint, spine, cervical, lumbar, transforaminal endoscopic operation, and ENT treatment applications. The company was founded in 2009 and is based in Shanghai, China.

MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

Beijing Genskey Technology Co., Ltd. is a medical diagnostic service provider specializing in genetic testing. Founded in 2007 and headquartered in Beijing, China, the company employs high-throughput sequencing technology combined with intelligent algorithm analysis to enhance pathogen diagnosis. Genskey aims to address common challenges in the medical diagnostics field, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of diagnostic results, Genskey seeks to ensure that patients suffering from severe infections receive prompt and accurate diagnoses, ultimately contributing to better health outcomes.

Shanghai Shenqi Medical Technology Co., Ltd. specializes in the research, development, production, and sale of minimally invasive vascular interventional products. Established in 2014 and based in Shanghai, the company provides a diverse range of medical devices including releasable embolization systems, peripheral microcatheters, distal access guide catheters, drug-coated coronary balloon catheters, and left atrial appendage occluder systems. These products are designed for various medical applications, including cardiovascular intervention, peripheral vascular intervention, neurovascular intervention, and the treatment of structural heart diseases. Shenqi Medical is committed to delivering innovative solutions for the healthcare industry in China.

Jabrehoo focusing on clinical transformation and innovative research and development of related products in the field of assisted reproduction, genetics and eugenics, providing one-stop solutions for reproductive genetics for assisted reproduction couples, infertile patients, and people who are preparing for pregnancy, and promoting the localization of various detections.

Immvira Co., Ltd. is a biopharmaceutical company based in Shenzhen, China, established in May 2015 by a team of renowned professors from various prestigious universities. The company specializes in the development of innovative anti-cancer therapies that utilize genetically engineered viruses. These therapies are designed to target cancer cells specifically and are enhanced by cancer-specific immune factors or chemotherapeutic agents. Immvira's product offerings include oncolytic herpes simplex viruses (oHSV) that encode interleukin-12 and anti-PD-1 antibodies, which can be delivered directly into tumor masses or in combination with systemic immune modulators. The company also explores auxiliary therapies and engineered viruses that can infect tumor cells with unique surface receptors.

Yachuang Pharmaceuticals is an innovative pharmaceutical research and development company focusing on liver diseases such as NASH and HBV. Founder Dr. Xu has worked in multinational pharmaceutical companies such as Johnson & Johnson, with over 20 years of successful innovation and management of innovative drugs. experience.

SinoMab Bioscience Limited is a biopharmaceutical company focused on the research, development, manufacture, and commercialization of therapeutics aimed at treating immunological diseases, primarily through monoclonal antibody (mAb)-based biologics. The company’s leading product, SM03 (Suciraslimab), is a first-in-target mAb currently in Phase III clinical trials for rheumatoid arthritis (RA) and is being investigated for additional applications in systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). Additionally, SinoMab is developing SN1011, a BTK inhibitor in Phase I trials for RA, SLE, and pemphigus, among others. The company also has several products in preclinical stages, including SM17 for asthma and idiopathic pulmonary fibrosis, SM09 for NHL and RA, SM06 for RA, NHL, SLE, and SS, and TNF2 for RA. Founded in 2001 and headquartered in Pak Shek Kok, Hong Kong, SinoMab operates primarily in Mainland China and Hong Kong.

Tavotek Biotherapeutics is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutic medicines for patients with severe diseases that lack effective treatments. The company is led by experienced pharmaceutical executives who have successfully developed numerous biologics currently on the market. Tavotek employs three distinct research and development platforms: TavoSelect, an innovative Phage Display Library; TavoPrecise, an engineering platform for tissue-specific biologics; and TavoMIP, a multicyclic peptide platform. This diverse array of technologies supports Tavotek's extensive pipeline of product candidates, which targets cancers, autoimmune disorders, and infectious diseases, thereby addressing significant unmet medical needs in the healthcare landscape.

Jousing Medical is a medical equipment supplier, which mainly provides automated external defibrillators.

Jiuxin Medical is a medical company that provides pre-hospital first-aid products and solutions for cardiovascular fields. The company was founded by a group of like-minded people who have mastered the industry's leading expertise and operational experience. The company has been approved for dozens of invention patents, and the products developed have complete independent intellectual property rights.